NexGard

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

afoxolaner

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QP53BE01

INN (International Name):

afoxolaner

Therapeutic group:

Klieb

Therapeutic area:

Isoxazolines, Ektoparasitaċidali għall-użu sistemiku

Therapeutic indications:

It-trattament tal-infestazzjoni mill-briegħed fil-klieb (Ctenocephalides felis u C. canis) għal mill-inqas 5 ġimgħat. Il-prodott jista 'jintuża bħala parti minn strateġija ta' trattament għall-kontroll tad-dermatite tal-allerġija tal-briegħed (FAD). It-trattament tal-infestazzjoni tal-qurdien fi klieb (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus). Trattament wieħed joqtol il-qurdien għal sa xahar. Il-briegħed u l-qurdien għandhom jingħaqdu ma 'l-ospitant u jibdew jgħumu sabiex ikunu esposti għas-sustanza attiva. Trattament ta ' domodicosis (ikkawżata minn Demodex canis). Kura għal sarcoptic mange (ikkawżata minn Sarcoptes scabiei var. canis).

Product summary:

Revision: 11

Authorization status:

Awtorizzat

Authorization date:

2014-02-11

Patient Information leaflet

                                15
B. FULJETT TA’ TAGĦRIF
16
FULJETT TA’ TAGĦRIF
NEXGARD 11 MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB 2−4 KG
NEXGARD 28 MG PILLOLI LI JINTMAGĦDU GĦAL
KLIEB
>
4−10 KG
NEXGARD 68 MG PILLOLI LI JINTMAGĦDU GĦAL
KLIEB
>
10−25 KG
NEXGARD 136 MG PILLOLI LI JINTMAGĦDU GĦAL
KLIEB > 25−50 KG
1.
L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-
TQEGĦID FIS-SUQ U TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAL-
MANIFATTURA RESPONSABBLI GĦAL-ĦRUĠ TAL-LOTT, JEKK DIFFERENTI
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
IL-ĠERMANJA
Manifattur responsabbli għal-ħrug tal-lott:
Boehringer Ingelheim Animal Health France SCS,
4 Chemin du Calquet,
31000 Toulouse,
Franza.
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
NexGard 11 mg pilloli li jintmagħdu għal klieb (2−4 kg)
NexGard 28 mg pilloli li jintmagħdu għal klieb (> 4−10 kg)
NexGard 68 mg pilloli li jintmagħdu għal klieb (> 10−25 kg)
NexGard 136 mg pilloli li jintmagħdu għal klieb (> 25−50 kg)
afoxolaner
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Kull pillola li tintmagħad fiha:
NEXGARD
AFOXOLANER (MG)
pilloli li jintmagħdu għal klieb 2−4 kg
11.3
pilloli li jintmagħdu għal klieb > 4−10 kg
28.3
pilloli li jintmagħdu għal klieb > 10−25 kg
68.0
pilloli li jintmagħdu għal klieb > 25−50 kg
136.0
Pilloli ħomor sa kannella fl-aħmar bid-dbabar, b’forma tonda
(pilloli għal-klieb 2−4 kg) jew b’forma
rettangolari (pilloli għal-klieb > 4−10 kg, pilloli għal-klieb
>10−25 kg u pilloli għal-klieb
> 25−50 kg).
4.
INDIKAZZJONI(JIET)
Kura ta’ infestazzjonijiet bi briegħed fil-klieb (_Ctenocephalides
felis u C. canis)_ għal mill-inqas
5 ġimgħat. Il-prodott jista’ jintuża bħala parti minn
strateġija ta’ kura għal-kontroll ta’ dermatite ta’
allerġija għal-briegħed (FAD).
17
Kura ta’ infestazzjonijiet b’qurdien fil-klieb (_Dermacentor
reticulatus, Ixodes ricinus, Ixodes _
_hexagonus, Rhipicephalus sanguineus)_. Kura waħd
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
NexGard 11 mg pilloli li jintmagħdu għal-klieb 2−4 kg
NexGard 28 mg pilloli li jintmagħdu għal-klieb >4−10 kg
NexGard 68 mg pilloli li jintmagħdu għal-klieb >10−25 kg
NexGard 136 mg pilloli li jintmagħdu għal-klieb >25−50 kg
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull pillola li tintmagħad fiha:
SUSTANZA ATTIVA:
NEXGARD
AFOXOLANER (MG)
pilloli li jintmagħdu għal klieb 2-4 kg
11.3
pilloli li jintmagħdu għal klieb > 4-10 kg
28.3
pilloli li jintmagħdu għal lieb >10-25 kg
68.0
pilloli li jintmagħdu għal klieb >25-50 kg
136.0
Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pilloli li jintmagħdu.
Pilloli ħomor sa kannella fl-aħmar bid-dbabar, b’forma tonda
(pilloli għal klieb 2-4 kg) jew b’forma
rettangolari pilloli għal klieb >4-10 kg, pilloli għal klieb >10-25
kg u pilloli għal klieb >25-50 kg).
4
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb
4.2
INDIKAZZJONIJIET GĦAL-UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Kura ta’ infestazzjonijiet bi briegħed fil-klieb (_Ctenocephalides
felis _u _C. canis)_ għal mill-inqas
5 ġimgħat. Il-prodott jista’ jintuża bħala parti minn
strateġija ta’ kura għal-kontroll ta’ dermatite ta’
allerġija għal-briegħed (FAD).
Kura ta’ infestazzjonijiet b’qurdien fil-klieb (_Dermacentor
reticulatus, Ixodes ricinus, Ixodes _
_hexagonus, Rhipicephalus sanguineus)_. Kura waħda toqtol il-qurdien
sa xahar.
Il-briegħed u l-qurdien iridu jeħlu mal-ospitant u jibdew jieklu
biex jiġu esposti għas-sustanza attiva.
Kura ta’ demodikosi (ikkawżata minn _Demodex canis_)
Kura ta’ sarcoptic mange (ikkawżata minn _Sarcoptes scabiei
var.canis_).
4.3
KONTRAINDIKAZZJONIJIET
Tużax f’każijiet ta’ sensittività għal-ingredjent attiv jew
għal xi wieħed mill-ingredjenti mhux attivi.
3
4.4
TWISSIJIET SPEĊJALI GĦAL KULL SPEĊI LI GĦALIHA 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 08-04-2020
Public Assessment Report Public Assessment Report Bulgarian 10-12-2018
Patient Information leaflet Patient Information leaflet Spanish 08-04-2020
Public Assessment Report Public Assessment Report Spanish 10-12-2018
Patient Information leaflet Patient Information leaflet Czech 08-04-2020
Public Assessment Report Public Assessment Report Czech 10-12-2018
Patient Information leaflet Patient Information leaflet Danish 08-04-2020
Public Assessment Report Public Assessment Report Danish 10-12-2018
Patient Information leaflet Patient Information leaflet German 08-04-2020
Public Assessment Report Public Assessment Report German 10-12-2018
Patient Information leaflet Patient Information leaflet Estonian 08-04-2020
Public Assessment Report Public Assessment Report Estonian 10-12-2018
Patient Information leaflet Patient Information leaflet Greek 08-04-2020
Public Assessment Report Public Assessment Report Greek 10-12-2018
Patient Information leaflet Patient Information leaflet English 08-04-2020
Public Assessment Report Public Assessment Report English 10-12-2018
Patient Information leaflet Patient Information leaflet French 08-04-2020
Public Assessment Report Public Assessment Report French 10-12-2018
Patient Information leaflet Patient Information leaflet Italian 08-04-2020
Public Assessment Report Public Assessment Report Italian 10-12-2018
Patient Information leaflet Patient Information leaflet Latvian 08-04-2020
Public Assessment Report Public Assessment Report Latvian 10-12-2018
Patient Information leaflet Patient Information leaflet Lithuanian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-04-2020
Public Assessment Report Public Assessment Report Lithuanian 10-12-2018
Patient Information leaflet Patient Information leaflet Hungarian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 08-04-2020
Public Assessment Report Public Assessment Report Hungarian 10-12-2018
Patient Information leaflet Patient Information leaflet Dutch 08-04-2020
Public Assessment Report Public Assessment Report Dutch 10-12-2018
Patient Information leaflet Patient Information leaflet Polish 08-04-2020
Public Assessment Report Public Assessment Report Polish 10-12-2018
Patient Information leaflet Patient Information leaflet Portuguese 08-04-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 08-04-2020
Public Assessment Report Public Assessment Report Portuguese 10-12-2018
Patient Information leaflet Patient Information leaflet Romanian 08-04-2020
Public Assessment Report Public Assessment Report Romanian 10-12-2018
Patient Information leaflet Patient Information leaflet Slovak 08-04-2020
Public Assessment Report Public Assessment Report Slovak 10-12-2018
Patient Information leaflet Patient Information leaflet Slovenian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 08-04-2020
Public Assessment Report Public Assessment Report Slovenian 10-12-2018
Patient Information leaflet Patient Information leaflet Finnish 08-04-2020
Public Assessment Report Public Assessment Report Finnish 10-12-2018
Patient Information leaflet Patient Information leaflet Swedish 08-04-2020
Public Assessment Report Public Assessment Report Swedish 10-12-2018
Patient Information leaflet Patient Information leaflet Norwegian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 08-04-2020
Patient Information leaflet Patient Information leaflet Icelandic 08-04-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 08-04-2020
Patient Information leaflet Patient Information leaflet Croatian 08-04-2020
Public Assessment Report Public Assessment Report Croatian 10-12-2018

Search alerts related to this product

View documents history